

---

# Hydrogen peroxide and cutaneous biology: Translational applications, benefits, and risks



Emily C. Murphy, BS,<sup>a,b</sup> and Adam J. Friedman, MD<sup>a</sup>  
Washington, DC

Hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) is an endogenous reactive oxygen species that contributes to oxidative stress directly as a molecular oxidant and indirectly through free radical generation. Topically applied 1% to 45% H<sub>2</sub>O<sub>2</sub> can be used for a range of clinical purposes, which will be reviewed here in addition to its safety. In concentrations from 1% to 6%, H<sub>2</sub>O<sub>2</sub> has antimicrobial properties and can act as a debriding agent through its effervescence, making low-concentration H<sub>2</sub>O<sub>2</sub> useful for wound care. H<sub>2</sub>O<sub>2</sub> has also been shown to promote venous insufficiency ulcer healing, but studies in other wound types are needed. In 1% formulations, H<sub>2</sub>O<sub>2</sub> is used outside the United States to treat acne and has shown efficacy similar to or greater than benzoyl peroxide, with reduced side effects. In a concentration of 40%, H<sub>2</sub>O<sub>2</sub> is US Food and Drug Administration–approved to treat seborrheic keratoses and may cause fewer pigmentary changes than cryotherapy, although elimination often requires 2 to 4 treatments. However, H<sub>2</sub>O<sub>2</sub> should be used with caution, as exposure can cause adverse effects through its oxidant capabilities. Low H<sub>2</sub>O<sub>2</sub> concentrations cause only transient symptoms (blanching and blistering), but exposure to 9% to 45% H<sub>2</sub>O<sub>2</sub> can cause more severe skin damage, including epidermal necrosis leading to erythema and bullae. Overall, H<sub>2</sub>O<sub>2</sub> has numerous therapeutic uses, and novel indications, such as treating actinic keratoses and skin cancers, continue to be explored. (J Am Acad Dermatol 2019;81:1379-86.)

**Key words:** actinic keratosis; antiseptic; free radicals; hydrogen peroxide; reactive oxygen species; seborrheic keratosis; skin cancer; Warburg effect; wound healing.

**H**ydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) is a reactive oxygen species (ROS) that can oxidatively damage lipids, proteins, and nucleic acids, either directly or indirectly through the formation of hydroxyl radicals (OH•) and downstream propagation of additional ROS.<sup>1</sup> Endogenous H<sub>2</sub>O<sub>2</sub> can be formed by cellular enzymatic reactions or the spontaneous dismutation of superoxide (O<sub>2</sub><sup>-</sup>) (Fig 1).<sup>1</sup> In contrast to O<sub>2</sub><sup>-</sup>, H<sub>2</sub>O<sub>2</sub> can diffuse across cell membranes and travel through different cellular or tissue compartments before decomposing.<sup>1</sup>

Given that free radicals can cause damage, enzymatic and nonenzymatic antioxidant activities have evolved. Antioxidant enzymes are particularly important for regulating endogenous H<sub>2</sub>O<sub>2</sub> (Fig 1)<sup>1</sup>

so that it can safely perform its roles, including acting as a secondary messenger in cell migration, proliferation, and apoptosis pathways; transcription factor regulator; chemokine inducer; and pathogen defense mechanism.<sup>2-6</sup> Through these activities, H<sub>2</sub>O<sub>2</sub> has a role in the skin, contributing to the innate immune system, apoptosis, wound healing, and superficial vessel tone.<sup>7-9</sup>

There are multiple uses for H<sub>2</sub>O<sub>2</sub> applied at supraphysiologic levels from 1% (~300 mM) to 45% (~13.5 M). In this review, we will discuss the applications of H<sub>2</sub>O<sub>2</sub> (Table 1<sup>10-22</sup>) in addition to important safety considerations. Low concentrations (1%-6%) are used as antimicrobials on intact skin or open wounds. High concentrations (10%-

---

From the George Washington University School of Medicine and Health Sciences, Washington, DC,<sup>a</sup> and Georgetown University, School of Medicine, Washington, DC.<sup>b</sup>

Funding sources: None.

Disclosure: Dr Friedman is a consultant for Aclaris Therapeutics, Inc. Editorial assistance was provided by Julie Ponting of Anthemis Consulting Ltd, funded by Aclaris Therapeutics, Inc. Ms Murphy has no conflicts of interest to disclose.

The authors were not compensated and retained full editorial control over the content of the article.

---

Accepted for publication May 12, 2019.

Reprints not available from the authors.

Correspondence to: Adam J. Friedman, MD, George Washington School of Medicine and Health Sciences, Department of Dermatology, 2150 Pennsylvania Ave, Suite 2B-430, Washington, DC 20037. E-mail: [ajfriedman@mfa.gwu.edu](mailto:ajfriedman@mfa.gwu.edu).

Published online May 16, 2019.

0190-9622/\$36.00

© 2019 by the American Academy of Dermatology, Inc.

<https://doi.org/10.1016/j.jaad.2019.05.030>

45%) are applied to intact skin, delivering a portion of the dose through the stratum corneum (Fig 2).<sup>23</sup> Articles were identified through a PubMed search for the terms *hydrogen AND peroxide AND skin AND (topical OR cream OR solution OR gel OR ointment)* in September 2018.

## APPLICATIONS

### 1% to 6% H<sub>2</sub>O<sub>2</sub>

#### Skin cleansing/antiseptic.

H<sub>2</sub>O<sub>2</sub> (3% in the United States, 6% in Europe) has been used since the 1850s for wound irrigation and disinfection and continues to be widely used as an over-the-counter antiseptic against bacteria, yeast, fungi, and viruses.<sup>24,25</sup> To exert its broad-spectrum action, H<sub>2</sub>O<sub>2</sub> produces hydroxyl radicals that damage cell components, leading to the breakdown of biofilms, cell membranes, and cell walls.<sup>26-29</sup> Release of oxygen from degradation of H<sub>2</sub>O<sub>2</sub>, called effervescence, also contributes to its antimicrobial efficacy by loosening debris, pus, and blood in wounds, which reduces bacterial colonization.<sup>30</sup> Compared with antibiotics, H<sub>2</sub>O<sub>2</sub> may have a lower risk of bacterial resistance. Ikai et al showed that 7 bacterial species did not develop resistance after 40 exposures to photolyzed 3% H<sub>2</sub>O<sub>2</sub>.<sup>31</sup> However, exposure to very low H<sub>2</sub>O<sub>2</sub> levels can increase resistance. In 1 study, pretreatment of *Salmonella typhimurium* with up to 100 μM H<sub>2</sub>O<sub>2</sub> increased resistance on subsequent administration, possibly because of induction of catalase expression.<sup>32</sup> H<sub>2</sub>O<sub>2</sub> and generated ROS likely evade resistance by exerting structurally and metabolically widespread oxidant effects.<sup>31</sup>

Outside the United States, over-the-counter creams with 1% H<sub>2</sub>O<sub>2</sub> (Microcid, Bioglan Pharma, Malmö, Sweden) or 1% lipid-stabilized H<sub>2</sub>O<sub>2</sub> (Crystacide, Mipharm, Milan, Italy) are available to treat superficial infections.<sup>10,11</sup> In a 3-week, randomized, double-blind trial of 256 patients with impetigo contagiosa, 1% H<sub>2</sub>O<sub>2</sub> demonstrated reduction in disease severity equivalent to that of the antibiotic Fucidin (LEO Pharma, Ballerup, Copenhagen, Denmark).<sup>10</sup>

Further antimicrobial applications have been explored. One study showed that 3% and 5% H<sub>2</sub>O<sub>2</sub> reduced the number of viable cells in *Staphylococcus epidermidis* biofilms on culture plates.<sup>33</sup> Other studies showed antimicrobial synergy of H<sub>2</sub>O<sub>2</sub> with iodine<sup>34</sup>

and chlorhexidine.<sup>35</sup> Using these antiseptics together may allow decreased dosing with lessened side effects.

**Wound care.** Endogenous H<sub>2</sub>O<sub>2</sub> plays a role in hemostasis,<sup>36,37</sup> initiation of inflammation and neo-angiogenesis,<sup>37,38</sup> and cell proliferation.<sup>37,39,40</sup> Given these characteristics, in addition to antimicrobial and debriding properties of H<sub>2</sub>O<sub>2</sub>, low H<sub>2</sub>O<sub>2</sub> concentrations may enhance wound healing.<sup>30,41</sup> However, there are concerns about the cytotoxicity, antiseptic efficacy, and short half-life of H<sub>2</sub>O<sub>2</sub>.<sup>28</sup>

To explore the antimicrobial efficacy of H<sub>2</sub>O<sub>2</sub>, Lau and Wong used 3% H<sub>2</sub>O<sub>2</sub> on appendectomy wounds before skin closure.<sup>42</sup> Toxic effects were not seen, but H<sub>2</sub>O<sub>2</sub> did not reduce infections in treated patients (n = 109) compared with controls (n = 108).<sup>42</sup> In another trial including 48 patients with experimentally induced intradermal blisters inoculated

with *Staphylococcus aureus*, application of 3% H<sub>2</sub>O<sub>2</sub> did not delay wound healing but also did not decrease bacterial loads compared with the bacterial loads of untreated blisters.<sup>43</sup>

The impact of H<sub>2</sub>O<sub>2</sub> on healing rates has also been explored. Two murine studies showed that wound irrigation with 3% H<sub>2</sub>O<sub>2</sub> did not delay re-epithelialization<sup>44</sup> or accelerated re-epithelialization compared with saline.<sup>45</sup> As for clinical trials, an early study found that using 3% H<sub>2</sub>O<sub>2</sub> every 6 hours on graft donor sites did not delay re-epithelialization compared with controls.<sup>45</sup> However, H<sub>2</sub>O<sub>2</sub> resulted in air-filled bullae in most patients after healing, possibly from released oxygen lifting the epidermis, suggesting that H<sub>2</sub>O<sub>2</sub> should not be applied to newly healed skin.<sup>45</sup> In a later study, bilateral burns were debrided and grafted (N = 49).<sup>46</sup> One limb was washed with 2% H<sub>2</sub>O<sub>2</sub>-soaked gauze for 5 minutes before grafting, which significantly increased grafting success compared with saline (83% graft take for H<sub>2</sub>O<sub>2</sub> vs 66% for saline).<sup>46</sup> Unlike in the earlier trial,<sup>45</sup> H<sub>2</sub>O<sub>2</sub> produced no adverse effects.<sup>46</sup> A retrospective study of 130 patients who underwent hydrosurgery involving jet lavage with or without H<sub>2</sub>O<sub>2</sub> to debride infected wounds was also done.<sup>47</sup> Patients who were hydrodebrided with H<sub>2</sub>O<sub>2</sub> had significantly shorter hospital stays, increased graft viability, and lower postoperative hemoglobin alterations, suggesting that reduced blood loss than patients debrided without H<sub>2</sub>O<sub>2</sub>.<sup>47</sup>

## CAPSULE SUMMARY

- Hydrogen peroxide is an endogenous reactive oxygen species that can be applied topically at supraphysiologic concentrations for therapeutic purposes.
- Hydrogen peroxide is commonly used as an antimicrobial and may promote wound healing, in part via its debriding properties. Recently, 40% hydrogen peroxide was US Food and Drug Administration–approved to treat seborrheic keratoses; other novel uses continue to be researched.

*Abbreviations used:*


AK:	actinic keratosis
H <sub>2</sub> O <sub>2</sub> :	hydrogen peroxide
O <sub>2</sub> <sup>-</sup> :	superoxide
OH <sup>+</sup> :	hydroxyl free radicals
PDT:	photodynamic therapy
ROS:	reactive oxygen species
SCC:	squamous cell carcinoma
SK:	seborrheic keratosis

Treatment of venous insufficiency ulcers with H<sub>2</sub>O<sub>2</sub> was also studied. Two 10-day, randomized trials involving a total of 52 patients evaluated daily application of 1% lipid-stabilized H<sub>2</sub>O<sub>2</sub>. Compared with placebo, H<sub>2</sub>O<sub>2</sub> significantly reduced ulcer area, plasma free radicals, and flux on laser Doppler flowmetry, indicating improved microcirculation.<sup>14,15</sup> The improved blood flow may have been due to activation of angiogenesis-promoting metalloproteinases by H<sub>2</sub>O<sub>2</sub>.<sup>38</sup> A similar study with 73 patients showed that longer H<sub>2</sub>O<sub>2</sub> treatment (eight weeks) also reduced venous inefficiency ulcer area compared to vehicle.<sup>16</sup> No adverse effects of H<sub>2</sub>O<sub>2</sub> were seen in these trials.<sup>14-16</sup> Therefore, H<sub>2</sub>O<sub>2</sub> may enhance wound healing, possibly by improving circulation.

Overall, H<sub>2</sub>O<sub>2</sub> does not negatively affect wound healing and may even improve healing. However, use in wound care is currently limited given that H<sub>2</sub>O<sub>2</sub> has had mixed results in clinical studies and may not reduce the bacterial burdens of wounds.<sup>42,43</sup>

**Acne.** Various antiacne H<sub>2</sub>O<sub>2</sub> formulations are available outside the United States. Two randomized, investigator-blind trials demonstrated that the efficacies of 1% lipid-stabilized H<sub>2</sub>O<sub>2</sub> alone<sup>12</sup> and with adapalene gel<sup>13</sup> are similar to<sup>12</sup> or greater than<sup>13</sup> the efficacies of benzoyl peroxide alone or with adapalene gel, respectively. H<sub>2</sub>O<sub>2</sub> also had higher tolerability than benzoyl peroxide.<sup>12,13</sup> Two forms of the H<sub>2</sub>O<sub>2</sub>-containing product Acnaid (Boderm, Attica, Greece) are available in Europe. The original form, Acnaid Gel Cosmetic, contains 4% H<sub>2</sub>O<sub>2</sub>, 0.5% salicylic acid, and 4% D-panthenol. A subsequent formulation, Acnaid gel medical device (3% H<sub>2</sub>O<sub>2</sub>, 1.5% salicylic acid, and 4% D-panthenol), was found to be effective in a small, uncontrolled study and to reduce acne symptoms to a greater degree than the original formulation did.<sup>48,49</sup> The authors proposed that H<sub>2</sub>O<sub>2</sub>-based formulations may be preferable to topical retinoids that increase sun sensitivity.<sup>48,49</sup>

**Skin cancer.** H<sub>2</sub>O<sub>2</sub> was explored as a photosensitizing agent for photodynamic therapy (PDT), which is commonly used to treat actinic keratoses (AKs) and is effective for some basal cell carcinomas.<sup>50</sup> The production of ROS in PDT leads to tissue damage, so its effectiveness depends on oxygen, which is increased by H<sub>2</sub>O<sub>2</sub>. Manifold and Anderson studied 1% lipid-stabilized H<sub>2</sub>O<sub>2</sub> as a photosensitizer with methylaminolevulinate.<sup>17</sup> Topical methylaminolevulinate (3-hour application) and red light (570-670 nm, 100 J/cm<sup>2</sup>) were administered to the forearms of 40 healthy volunteers at low-oxygen, H<sub>2</sub>O<sub>2</sub>-treated, and control sites.



**Fig 1.** Production and degradation of hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>). Superoxide (O<sub>2</sub><sup>-</sup>) and H<sub>2</sub>O<sub>2</sub> are produced from endogenous and environmental sources. Transition metals (iron, copper) can catalyze the formation of hydroxyl free radicals (OH<sup>•</sup>), hydroxide (OH<sup>-</sup>), and oxygen (O<sub>2</sub>) through the Haber-Weiss reaction from O<sub>2</sub><sup>-</sup> and H<sub>2</sub>O<sub>2</sub>. OH<sup>•</sup> can then react with DNA, proteins, and lipids to cause tissue damage. To protect the body from free radical damage, antioxidant enzymes catalase (complexed to iron), glutathione peroxidases and reductase, and peroxiredoxin degrade H<sub>2</sub>O<sub>2</sub> to water (H<sub>2</sub>O) and O<sub>2</sub>.

**Table I.** Common applications of H<sub>2</sub>O<sub>2</sub>

Product	Concentration	Use
Antiseptic/wound healing		
Microcid (Bioglan Pharma, Malmö, Sweden)	1%	Treatment of skin infections (OTC, outside the United States) <sup>10,11</sup>
Crystacide (Mipharm, Milan, Italy)	1% lipid-stabilized	Treatment of skin infections, <sup>10,11</sup> acne vulgaris, <sup>12,13</sup> and venous insufficiency ulcers <sup>14-16</sup> (OTC, outside the United States)
Acnaid (Boderm, Attica, Greece)	4% H <sub>2</sub> O <sub>2</sub> , 0.5% salicylic acid, and 4% D-panthenol (OTC); 3% H <sub>2</sub> O <sub>2</sub> , 1.5% salicylic acid, and 4% D-panthenol (prescription)	Treatment of acne vulgaris (OTC/prescription, outside the United States) <sup>48,49</sup>
Various solutions	3% in US; 6% in Europe	Infection prevention for cuts/scrapes/burns (OTC)
Benign and malignant skin tumors		
Crystacide	1% lipid-stabilized	Treatment of skin cancers with PDT (research) <sup>17</sup>
Oxydol (Procter & Gamble, Cincinnati, Ohio)	3%	Radiosensitizer for treatment of unresectable neoplasms (research) <sup>18</sup>
Unnamed gel	25%	Treatment of AKs with sulindac gel (Sigma-Aldrich, St. Louis, Missouri) (research) <sup>19</sup>
Eskata (Aclaris Therapeutics, Wayne, PA)	40%	Treatment of SKs (prescription) <sup>20,21</sup>
Other uses		
A101 (40-45% hydrogen peroxide, Aclaris Therapeutics, Wayne, PA)	40% or 45%	Treatment of common warts (research).
Various solutions	3%-6%	Hair bleaching (OTC) <sup>22</sup>

Availability is noted under use (OTC, prescription, or for research purposes only); products are available in the United States unless otherwise specified.

AK, Actinic keratosis; OTC, over the counter; PDT, photodynamic therapy; SK, seborrheic keratosis.


Oxygen availability was lowered at 1 site by applying blanching pressure with a slide. The ability of H<sub>2</sub>O<sub>2</sub> to reverse this deoxygenation was examined by applying H<sub>2</sub>O<sub>2</sub> before blanching. Erythema was visually observed and assessed with laser Doppler perfusion imaging, with reduced erythema suggesting decreased PDT efficacy. The percentages of sites showing no visible erythema were 7.5% for the control sites, 7.5% for H<sub>2</sub>O<sub>2</sub>-treated sites, and 17.5% for the low-oxygen sites. Thus, pretreating with H<sub>2</sub>O<sub>2</sub> offset the effects of low oxygen. Laser Doppler perfusion imaging showed that compared with control sites, low-oxygen sites had decreased perfusion after 24 hours whereas H<sub>2</sub>O<sub>2</sub> sites had increased perfusion. Thus, H<sub>2</sub>O<sub>2</sub> may enhance the efficacy of PDT by increasing oxygen.<sup>17</sup>

H<sub>2</sub>O<sub>2</sub> was additionally evaluated as a radiosensitizing agent. Radiation generates oxygen-derived free radicals, so H<sub>2</sub>O<sub>2</sub> may enhance radiation's efficacy by increasing ROS. Five patients with superficial, unresectable neoplasms (melanoma, malignant fibrous histiocytoma, extramammary Paget disease, breast cancer, and squamous cell carcinoma [SCC]) were treated with electron beam radiation (48 Gy) 3 times per week for 1 to 3 months.<sup>18</sup> After radiation, the

tumors were covered with 3% H<sub>2</sub>O<sub>2</sub>-soaked gauze for several minutes. Two patients showed complete responses, and 3 showed greater than 50% reductions in tumor volume. No severe complications occurred, but everyone experienced mild radiation dermatitis and/or mucositis.<sup>18</sup> A related study examined intratumor injection of 0.5% hydrogen peroxide and 0.83% sodium hyaluronate as radiosensitizing agents (1-2 times/wk for 3 weeks before radiation) for nonsuperficially exposed neoplasms.<sup>51</sup> Of 11 patients (7 with breast cancer and the others with malignant fibrous histiocytoma, malignant schwannoma, SCC, or fibrosarcoma), 9 patients experienced complete responses, 1 showed a partial response, and 1 experienced no change. These studies support the idea that H<sub>2</sub>O<sub>2</sub> may act as a radiosensitizing agent, although larger controlled studies are needed.<sup>18</sup>

### 25% to 45% H<sub>2</sub>O<sub>2</sub>

**Mechanism.** By forming free radicals and oxygen at the stratum corneum, low-concentration H<sub>2</sub>O<sub>2</sub> can damage microbial structures and act as a debriding agent. When applied to wounded skin, low-concentration H<sub>2</sub>O<sub>2</sub> may penetrate deeper into the skin, exerting further oxidative damage and



**Fig 2.** Application of high-concentration hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) (10%–45%). **A**, High-concentration H<sub>2</sub>O<sub>2</sub> essentially acts as a delivery system—a fraction of the applied dose diffuses through the stratum corneum and into the epidermis, where it breaks down into oxygen and water and is converted to hydroxyl radicals (OH•). These free radicals can then overwhelm the skin’s antioxidant system and drive oxidative stress–triggered apoptosis or necrosis of sensitive cells. **B**, The stratum corneum acts as a barrier, protecting deeper tissue from high concentrations of H<sub>2</sub>O<sub>2</sub> and is thus necessary for safe use.<sup>23</sup> In wounded skin without an intact stratum corneum, high-concentration H<sub>2</sub>O<sub>2</sub> will cause rapid necrosis and apoptosis of surrounding cells.

altering blood circulation. In contrast, high-concentration H<sub>2</sub>O<sub>2</sub> can be applied only to intact skin<sup>23</sup> and acts as a vehicle, delivering a portion of the dose to the epidermis, where it induces oxidative stress and cellular apoptosis and/or necrosis (Fig 2). High-concentration H<sub>2</sub>O<sub>2</sub> is used to treat seborrheic keratoses (SKs) and is being explored for the treatment of AKs. Although the mechanisms by which H<sub>2</sub>O<sub>2</sub> eliminates AKs and SKs are not completely understood, consideration of the Warburg effect suggests an explanation. The abnormal keratinocytes of SKs and AKs may be more sensitive to the oxidative stress induced by H<sub>2</sub>O<sub>2</sub> than other cells, given that transformed cells

experience a shift, termed the *Warburg effect*, from oxidative to glycolytic metabolism even with functional mitochondria. Although the Warburg effect confers certain advantages, it also renders transformed cells more susceptible to even brief exposures of oxidative stress,<sup>52,53</sup> which may explain the superior elimination of abnormal keratinocytes compared with nontransformed cells by H<sub>2</sub>O<sub>2</sub>.<sup>1,20,54</sup>

**SK.** Despite SKs being benign, patients frequently seek treatment for them for cosmetic reasons or symptomatic relief.<sup>55</sup> Liquid nitrogen cryotherapy, one of the most common techniques to remove SKs,<sup>56</sup> can cause blistering, scarring, and pigmentary changes, especially in dark-skinned

individuals.<sup>57</sup> Topical treatments, including 40% H<sub>2</sub>O<sub>2</sub> (HP40, Eskata, Aclaris Therapeutics, Wayne, PA), which is US Food and Drug Administration–approved to treat raised SKs, may limit these side effects.<sup>20</sup> The efficacy of HP40 for treating 4 SKs per patient was evaluated in 2 phase 3 studies involving a total of 937 patients.<sup>20</sup> Patients received HP40 or vehicle for 1 or 2 treatments depending on their responses. By day 106, significantly more patients using HP40 (4% and 8% per study, respectively) than vehicle (0% in both studies) attained complete clearance of all 4 SKs. A post hoc analysis found that HP40 led to a higher mean per-patient percentage of clear or nearly clear lesions than did vehicle (51% for HP40 vs 7% for vehicle). Additional sub-analysis showed that the anatomic location predicted treatment response, possibly because of regional histologic and physiologic differences.<sup>21</sup> The percentage of total SKs graded as clear/nearly clear was higher for the face than for other regions (65% for the face versus 46% for the trunk and 38% for the extremities).<sup>21</sup> Overall, the success of 1 or 2 treatments is limited, producing only about 50% clearance per patient. Further, repeat treatments are almost always needed (97% of the study sample required retreatment), which may be cost-prohibitive for some patients, given that this therapy is not covered by insurance. Adverse effects included only local skin reactions, with most being mild to moderate. Scarring, hypopigmentation, and hyperpigmentation were seen in less than 1%, 3%, and 8% of HP40-treated sites, respectively. However, 98.8% of the patients treated had Fitzpatrick skin types I to IV, so the effects on darker skin could not be assessed.<sup>20</sup> Another study used an *ex vivo* model of human Fitzpatrick type V skin to examine overall cytotoxicity (methyl thiazolyl tetrazolium assay) and melanocyte toxicity (counting of S100-stained melanocytes within high-power fields) of HP40. Compared with cryotherapy (5- or 10-second cycles), HP40 (1 or 2  $\mu$ L) was less cytotoxic overall and to melanocytes.<sup>58</sup> Therefore, H<sub>2</sub>O<sub>2</sub> may be superior for patients with Fitzpatrick type V skin, but clinical trials are needed to compare the efficacy of HP40 and associated risk of pigmentary changes with those of cryotherapy in patients with all skin types.

**AK.** In a concentration of 25%, H<sub>2</sub>O<sub>2</sub> combined with sulindac, an anti-inflammatory agent with anti-cancer effects, was explored to treat AKs.<sup>19</sup> In vitro studies with SCC cells showed that sulindac and *tert*-butyl hydroperoxide (used for its high stability) together increased cytotoxicity and intracellular ROS compared with either treatment alone. Therefore, consistent with the Warburg effect, the authors theorized that cancer cells will be more sensitive to

H<sub>2</sub>O<sub>2</sub>-induced oxidative stress than nontransformed cells are. In an open-label, uncontrolled study, patients applied sulindac gel plus 25% H<sub>2</sub>O<sub>2</sub> daily for 3 weeks. Of 10 AKs, 6 showed partial or complete reductions in size, with 5 of these showing no residual histopathologic involvement. Thus, as in the case of SKs, H<sub>2</sub>O<sub>2</sub>-derived ROS may reduce AKs.<sup>19</sup>

**Common wart.** The effectiveness of 40% to 45% H<sub>2</sub>O<sub>2</sub> for treatment of common warts is being examined in phase 2 (NCT03278028) and phase 3 (NCT03691831, NCT03687372) clinical trials.

## SAFETY

H<sub>2</sub>O<sub>2</sub> can be toxic to the skin through oxidative damage and oxygen formation, which can disrupt the epidermis, leading to vacuolar eruptions.<sup>23,59,60</sup> According to a retrospective review of exposures reported to a poison center, low H<sub>2</sub>O<sub>2</sub> concentrations caused only transient symptoms, including paresthesias, blanching, and blistering.<sup>61</sup> Although the mechanism of blanching is not fully elucidated, experiments using diffuse reflectance spectroscopy to measure the skin's optical properties have provided insight. Application of 3% to 6% H<sub>2</sub>O<sub>2</sub> to the forearms of healthy volunteers did not alter melanin concentrations but caused transient changes in oxyhemoglobin, suggesting that H<sub>2</sub>O<sub>2</sub> reached the epidermis and possibly the dermis, where capillaries are located.<sup>62</sup> It is possible, though, that H<sub>2</sub>O<sub>2</sub> decomposed in the epidermis and only the resulting oxygen reached the dermis.<sup>62</sup> The authors suggested that H<sub>2</sub>O<sub>2</sub> may interact with nitric oxide receptors, causing venule constriction.<sup>63</sup> Consistent with this, an *in vitro* murine model demonstrated H<sub>2</sub>O<sub>2</sub>-induced arterial constriction.<sup>64</sup> Rapid breakdown of H<sub>2</sub>O<sub>2</sub>, however, makes systemic effects unlikely.

Contact with higher H<sub>2</sub>O<sub>2</sub> concentrations can cause concentration- and length-dependent adverse effects. Case reports have shown that hair bleaching with 9% H<sub>2</sub>O<sub>2</sub> can cause full-thickness scalp burns requiring grafting.<sup>22,65</sup> The mechanism of bleaching-induced damage was explored in human hair and rat skin. Jeong et al applied ammonium persulfate and 6% to 9% H<sub>2</sub>O<sub>2</sub> before wrapping hair/rat skin in aluminum foil and heating for 15 to 30 minutes.<sup>66</sup> After 15 minutes, scanning electron microscopy showed that human hair cuticle scales were lifted, removed, or fractured. However, mechanical properties (tensile strength and elongation) did not change. On histology, rat skin showed extracellular matrix damage after 15 minutes and epidermal thinning and subepidermal vesicles after 30 minutes.<sup>66</sup> In another report, prolonged exposure to 35% H<sub>2</sub>O<sub>2</sub> through wet clothes resulted in focal epidermal necrosis leading to erythema, purpura,

and bullae.<sup>59</sup> Histologically, collagen and vascular degradation were seen.<sup>59</sup>

Overall, 1% to 6% H<sub>2</sub>O<sub>2</sub> causes only transient symptoms, but higher concentrations used for hair bleaching and industrial or experimental applications can cause severe chemical burns.<sup>22,59,65</sup> Caregivers, whether hair stylists, nurses, or physicians, must adhere to product instructions and cease treatments if users experience discomfort.

## CONCLUSION

H<sub>2</sub>O<sub>2</sub> is used for an array of applications through its oxidant effects and generation of ROS and oxygen. In concentrations of 1% to 6%, H<sub>2</sub>O<sub>2</sub> can be used as an antiseptic, to debride wounds, and to promote healing. However, research on the antimicrobial efficacy of H<sub>2</sub>O<sub>2</sub> is equivocal; instead, H<sub>2</sub>O<sub>2</sub> may be more effective as a debriding agent.<sup>39,46</sup> Similarly, the ability of H<sub>2</sub>O<sub>2</sub> to promote wound healing is contentious, with some studies reporting benefit<sup>14-16,46,47</sup> and others not.<sup>42,43</sup> Low H<sub>2</sub>O<sub>2</sub> concentrations have also shown value in treating acne, although these products are not available in the United States.<sup>12,13,48</sup> H<sub>2</sub>O<sub>2</sub> in concentrations of 25% to 40% are being studied to treat skin tumors. Notably, 40% H<sub>2</sub>O<sub>2</sub> is US Food and Drug Administration—approved to treat SKs and may lead to fewer pigmentary changes than cryotherapy does.<sup>20,21,58</sup> Despite these applications, H<sub>2</sub>O<sub>2</sub> can cause adverse effects and must be used with caution.

The authors would like to thank Dr Evan Dick, an employee of Aclaris Therapeutics, Inc, for his review of the article. Editorial assistance was provided by Julie Ponting of Anthemis Consulting Ltd, funded by Aclaris Therapeutics, Inc.

## REFERENCES

1. Young I, Woodside J. Antioxidants in health and disease. *J Clin Pathol*. 2001;54(3):176-186.
2. Afanas'ev I. Signaling by reactive oxygen and nitrogen species in skin diseases. *Curr Drug Metab*. 2010;11(5):409-414.
3. Marinho HS, Real C, Cyrne L, Soares H, Antunes F. Hydrogen peroxide sensing, signaling and regulation of transcription factors. *Redox Biol*. 2014;2:535-562.
4. Stone J, Yang S. Hydrogen peroxide: a signaling messenger. *Antioxid Redox Signal*. 2006;8(3-4):243-270.
5. Winterbourn C, Kettle A, Hampton M. Reactive oxygen species and neutrophil function. *Annu Rev Biochem*. 2016;85:765-792.
6. Veal E, Day A, Morgan B. Hydrogen peroxide sensing and signaling. *Mol Cell*. 2007;26(1):1-14.
7. Pugliese P. The skin's antioxidant systems. *Dermatol Nurs*. 1998;10(6):401.
8. Schafer M, Werner S. The cornified envelope: a first line of defense against reactive oxygen species. *J Invest Dermatol*. 2011;131(7):1409-1411.
9. Schallreuter K, Wood J. Free radical reduction in the human epidermis. *Free Radic Biol Med*. 1989;6(5):519-532.
10. Christensen OB, Anehus S. Hydrogen peroxide cream: an alternative to topical antibiotics in the treatment of impetigo contagiosa. *Acta Derm Venereol*. 1994;74:460-462.
11. Alsterholm M, Karami N, Faergemann J. Antimicrobial activity of topical skin pharmaceuticals - an in vitro study. *Acta Derm Venereol*. 2010;90(3):239-245.
12. Milani M, Bigardi A, Zavattarelli M. Efficacy and safety of stabilised hydrogen peroxide cream (Crystacide) in mild-to-moderate acne vulgaris: a randomised, controlled trial versus benzoyl peroxide gel. *Curr Med Res Opin*. 2003;19(2):135-138.
13. Capizzi R, Landi F, Milani M, Amerio P. Skin tolerability and efficacy of combination therapy with hydrogen peroxide stabilized cream and adapalene gel in comparison with benzoyl peroxide cream and adapalene gel in common acne. A randomized, investigator-masked, controlled trial. *Br J Dermatol*. 2004;151(2):481-484.
14. Belcaro G, Cesarone MR, Nicolaidis AN, et al. Improvement of microcirculation and healing of venous hypertension and ulcers with Crystacide. Evaluation of free radicals, laser Doppler flux and PO<sub>2</sub>. A prospective-randomized-controlled study. *Angiology*. 2003;54(3):325-330.
15. Belcaro G, Cesarone MR, Errichi BM, et al. Improvement of microcirculation and healing of venous hypertension and ulcers with Crystacide: evaluation with a microcirculatory model, including free radicals, laser Doppler flux, and PO<sub>2</sub>/PCO<sub>2</sub> measurements. *Angiology*. 2007;58(3):323-328.
16. Cesarone MR, Belcaro G, Errichi BM, et al. Faster healing of venous ulcers with crystacide: a clinical and microcirculatory 8-week registry study. *Panminerva Med*. 2010;52(2 Suppl 1):11-14.
17. Manifold RN, Anderson CD. Increased cutaneous oxygen availability by topical application of hydrogen peroxide cream enhances the photodynamic reaction to topical 5-aminolevulinic acid-methyl ester. *Arch Dermatol Res*. 2011;303:285-292.
18. Ogawa Y, Ue H, Tsuzuki K, et al. New radiosensitization treatment (KORTUC I) using hydrogen peroxide solution-soaked gauze bolus for unresectable and superficially exposed neoplasms. *Oncol Rep*. 2008;19(6):1389-1394.
19. Resnick L, Rabinovitz H, Binninger D, Marchetti M, Weissbach H. Topical sulindac combined with hydrogen peroxide in the treatment of actinic keratoses. *J Drugs Dermatol*. 2009;8(1):29-32.
20. Baumann LS, Blauvelt A, Draelos ZD, et al. Safety and efficacy of hydrogen peroxide topical solution, 40% (w/w), in patients with seborrheic keratoses: results from 2 identical, randomized, double-blind, placebo-controlled, phase 3 studies (A-101-SEBK-301/302). *J Am Acad Dermatol*. 2018;79(5):869-877.
21. Smith S, Xu S, Estes E, Shanler S. Anatomic site-specific treatment response with 40% hydrogen peroxide (w/w) topical formulation for raised seborrheic keratoses: pooled analysis of data from two phase 3 studies. *J Drugs Dermatol*. 2018;17(10):1092-1098.
22. Forster K, Lingitz R, Prattes G, et al. Hair bleaching and skin burning. *Ann Burns Fire Disasters*. 2012;25(4):200-202.
23. Bito T, Izu K, Tokura Y. Evaluation of toxicity and Stat3 activation induced by hydrogen peroxide exposure to the skin in healthy individuals. *J Dermatol Sci*. 2010;58(2):157-159.
24. Richardson BW. On the introduction of peroxide of hydrogen as a medicine. *Lancet*. 1866;87(2220):300.
25. Richardson BW. On peroxide of hydrogen, or ozone water, as a remedy. *Lancet*. 1891;137(3526):707-709.
26. McDonnell G, Russell A. Antiseptics and disinfectants: activity, action, and resistance. *Clin Microbiol Rev*. 1999;12(1):147-179.
27. Linley E, Denyer SP, McDonnell G. Use of hydrogen peroxide as a biocide: new consideration of its mechanisms of biocidal action. *J Antimicrob Chemother*. 2012;67(7):1589-1596.

28. Cambiaso-Daniel J, Boukavalas S, Bitz GH. Topical antimicrobials in burn care: part 1-topical antiseptics. *Ann Plast Surg*. 2019. <https://doi.org/10.1097/SAP.0000000000001297> [Epub ahead of print]. Accessed February 13, 2019.
29. Imlay J, Chin S, Linn S. Toxic DNA damage by hydrogen peroxide through the Fenton reaction in vivo and in vitro. *Science*. 1988;240(4852):640-642.
30. Rodeheaver GT. Wound cleansing, wound irrigation, wound disinfection. In: Krasner DL, Rodeheaver GT, Sibbald RG, Woo KY, eds. *Chronic Wound Care: A Clinical Source Book for Healthcare Professionals*. 2nd ed. Wayne, PA: Health Management Publications, Inc.; 1997:97-108.
31. Ikai H, Odashima Y, Kanno T, et al. In vitro evaluation of the risk of inducing bacterial resistance to disinfection treatment with photolysis of hydrogen peroxide. *PLoS One*. 2013;8(11):e81316.
32. Winquist L, Rannug U, Rannug A. Protection from toxic and mutagenic effects of H<sub>2</sub>O<sub>2</sub> by catalase induction in *Salmonella typhimurium*. *Mutat Res*. 1984;141(3-4):145-147.
33. Presterl E, Suchomel M, Eder M. Effects of alcohols, povidone-iodine and hydrogen peroxide on biofilms of *Staphylococcus epidermidis*. *J Antimicrob Chemother*. 2007;60(2):417-420.
34. Zubko EI, Zubko MK. Co-operative inhibitory effects of hydrogen peroxide and iodine against bacterial and yeast species. *BMC Res Notes*. 2013;15(6):272.
35. Steinberg D, Heling I, Daniel I. Antibacterial synergistic effect of chlorhexidine and hydrogen peroxide against *Streptococcus sobrinus*, *Streptococcus faecalis* and *Staphylococcus aureus*. *J Oral Rehabil*. 1999;26(2):151-156.
36. Pignatelli P, Pulcinelli FM, Lenti L, Gazzaniga PP, Violi F. Hydrogen peroxide is involved in collagen-induced platelet activation. *Blood*. 1998;91(2):484-490.
37. Sen CK, Roy S. Redox signals in wound healing. *Biochim Biophys Acta*. 2008;1780(11):1348-1361.
38. Tur E, Bolton L, Constantine BE. Topical hydrogen peroxide treatment of ischemic ulcers in the guinea pig: blood recruitment in multiple skin sites. *J Am Acad Dermatol*. 1995; 33(2 Pt 1):217-221.
39. Burdon RH. Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. *Free Radic Biol Med*. 1995;18(4): 775-794.
40. Zhu G, Wang Q, Lu S, Niu Y. Hydrogen peroxide: a potential wound therapeutic target? *Med Princ Pract*. 2017;26(4):301-308.
41. Drosou A, Falabella A, Kirsner R. Antiseptics on wounds: an area of controversy. *Wounds*. 2003;15(6):149-166.
42. Lau WY, Wong SH. Randomized, prospective trial of topical hydrogen peroxide in appendectomy wound infection. High risk factors. *Am J Surg*. 1981;142(3):383-397.
43. Leyden JJ, Bartelt NM. Comparison of topical antibiotic ointments, a wound protectant, and antiseptics for the treatment of human blister wounds contaminated with *Staphylococcus aureus*. *J Fam Pract*. 1987;24(6):601-604.
44. Lineaweaver W, Howard R, Soucy D, et al. Topical antimicrobial toxicity. *Arch Surg*. 1985;120(3):267-270.
45. Gruber R, Vistnes L, Pardoe R. The effect of commonly used antiseptics on wound healing. *Plast Reconstr Surg*. 1975;55(4): 472-476.
46. Mohammadi A, Seyed Jafari S, Kiasat M, Pakyari M, Ahrari I. Efficacy of debridement and wound cleansing with 2% hydrogen peroxide on graft take in the chronic-colonized burn wounds; a randomized controlled clinical trial. *Burns*. 2013;39(6):1131-1136.
47. Irkoren S, Sivrioglu N. A hydrosurgery system (Versajet) with and without hydrogen peroxide solutions for the debridement of subacute and chronic wounds: a comparative study with hydrodebridement. *Adv Skin Wound Care*. 2014;27(3):127-131.
48. Fabbrocini G, Panariello L. Efficacy and tolerability of a topical gel containing 3% hydrogen peroxide, 1.5% salicylic acid and 4% D-panthenol in the treatment of mild-moderate acne. *G Ital Dermatol Venereol*. 2016;151(3):287-291.
49. Ricci F, Masini F, Fossati B, et al. Combination therapy with hydrogen peroxide (4%), salicylic acid (0.5%) and D-panthenol (4%): efficacy and skin tolerability in common acne vulgaris during sun exposure period. *Eur Rev Med Pharmacol Sci*. 2016; 20(2):232-236.
50. Braathen LR, Szeimies R-M, Basset-Seguín N, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. *J Am Acad Dermatol*. 2007;56(1):125-143.
51. Ogawa Y, Kubota K, Ue H, et al. Phase I study of a new radiosensitizer containing hydrogen peroxide and sodium hyaluronate for topical tumor injection: a new enzyme-targeting radiosensitization treatment, Kochi Oxydol-radiation therapy for unresectable carcinomas, Type II (KORTUC II). *Int J Oncol*. 2009;34(3):609-618.
52. Libertini M, Locasale J. The Warburg effect: how does it benefit cancer cells? *Trends Biochem Sci*. 2016;41(3):211-218.
53. Liu J, Wang Z. Increased oxidative stress as a selective anticancer therapy. *Oxid Med Cell Longev*. 2015;2015:294303.
54. Yoon JJ, Jeong J-W, Choi EO, et al. Protective effects of *Scutellaria baicalensis* Georgi against hydrogen peroxide-induced DNA damage and apoptosis in HaCaT human skin keratinocytes. *EXCLI J*. 2017;16:426-438.
55. Del Rosso JQ. A closer look at seborrheic keratoses: patient perspectives, clinical relevance, medical necessity, and implications for management. *J Clin Aesthet Dermatol*. 2017;10(3): 16-25.
56. Farhangian ME, Snyder A, Huang KE, Doerfler L, Huang WW, Feldman SR. Cutaneous cryosurgery in the United States. *J Dermatolog Treat*. 2016;27(1):91-94.
57. Andrews MD. Cryosurgery for common skin conditions. *Am Fam Physician*. 2004;69(10):2365-2372.
58. Kao S, Kiss A, Efimova T, Friedman A. Ex vivo evaluation of cytotoxicity and melanocyte viability after A-101 hydrogen peroxide topical solution 40% or cryosurgery treatment in seb-orrheic keratosis lesions. *J Am Acad Dermatol*. 2018;79(4):767-768.
59. Izu K, Yamamoto O, Asahi M. Occupational skin injury by hydrogen peroxide. *Dermatology*. 2000;201(1):61-64.
60. Chan HP, Maibach HI. Hydrogen peroxide, blanching, and skin: an overview. *Cutan Ocul Toxicol*. 2008;27(4):307-309.
61. Dickson KF, Caravati EM. Hydrogen peroxide exposure—325 exposures reported to a regional poison control center. *J Toxicol Clin Toxicol*. 1994;32(6):705-714.
62. Zonios G, Dimou A, Galaris D. Probing skin interaction with hydrogen peroxide using diffuse reflectance spectroscopy. *Phys Med Biol*. 2008;53(1):269-278.
63. Stamatas G, Kollias N. Blood stasis contributions to the perception of skin pigmentation. *J Biomed Opt*. 2004;9(2):315-322.
64. Ardanaz N, Beierwaltes WH, Pagano PJ. Distinct hydrogen peroxide-induced constriction in multiple mouse arteries: potential influence of vascular polarization. *Pharmacol Rep*. 2008;60(1):61-67.
65. Maguina P, Shah-Khan M, An G, Hanumadass M. Chemical scalp burns after hair highlights. *J Burn Care Res*. 2007;28(2): 361-363.
66. Jeong MS, Lee CM, Jeong WJ. Significant damage of the skin and hair following hair bleaching. *J Dermatol*. 2010;37(10): 882-887.